Asia On The Move: China Startups Go On Hiring Spree
This article was originally published in PharmAsia News
As investment pours into Chinese biologic startups, a talent hunt is on, underscored by two announcements of new senior appointments at CANbridge and Zai Lab. Meanwhile, clinical research organization ICON has appointed new leadership for Asia and Meiji Seika is strengthening its CNS business.
You may also be interested in...
In a bold move to expand into cancer treatment markets, Siemens Healthineers has agreed to a $16.4bn all-cash deal to acquire radiation therapy leader Varian.
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.